Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial
Journal of Infection·
- DOI
- 10.1016/j.jinf.2026.106784
- PMID
- 42248304
- PMCID
- —
- OpenAlex
- W7163534422
- Study type
- Randomised controlled trial
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The documented compatibility indicates potential administrative advantages for coordinating seasonal and shingles immunisations within standard adult care pathways.
Structured evidence summary
Research question
This investigation assesses whether administering a recombinant zoster immunisation alongside either an mRNA coronavirus vaccine or an adjuvanted influenza formulation alters immune protection or increases adverse reactions.
Study design
The research utilises a multicentre, masked, randomised controlled non-inferiority phase four trial structure distributed across thirteen clinical locations.
Population and setting
Participants consisted of healthy adults aged fifty years and older recruited from multiple regional sites.
Main findings
Immune markers for all three vaccine types satisfied non-inferiority benchmarks one month after dosing. Reported severe systemic reactions remained infrequent overall, though frequencies showed a modest rise when shots were delivered simultaneously, reaching a maximum of 3.3 percent.
Public-health relevance
The documented compatibility indicates potential administrative advantages for coordinating seasonal and shingles immunisations within standard adult care pathways.
Important limitations
This assessment depends entirely on the provided abstract and bibliographic records, requiring the complete manuscript for rigorous appraisal. The trial also restricted enrollment to healthy older individuals, which may constrain applicability to other demographic groups.
GIDS interpretation
The work aligns with ongoing academic discourse regarding combined vaccination protocols and may appear in database queries targeting adult immunisation efficiency and cross-product compatibility.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.